

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
NATIONAL MEDICAL PRODUCTS ADMINISTRATION'S APPROVAL
OF CLINICAL TRIAL APPLICATION FOR BIVALENT COVID-19
MRNA VACCINE

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that, the clinical trial application for the Bivalent COVID-19 mRNA Vaccine developed by the Group was approved by the National Medical Products Administration of China. The vaccine is jointly applied by the Company and its subsidiaries, CanSino (Shanghai) Biological Research & Development Co., Ltd. and CanSino (Shanghai) Biotechnology Co., Ltd. Results of pre-clinical studies showed that, as compared to univalent COVID-19 vaccine, Bivalent COVID-19 mRNA Vaccine can elicit neutralising antibody with better cross-variant reactivity against the original strain, Omicron BA.1, BA.2.75, BA.4/5 and XBB.1. The toxicology studies results of the Bivalent COVID-19 mRNA Vaccine showed its high safety profile and promising clinical potential in development and providing more effective protection against infections caused by circulating variants.

The mRNA technology platform developed by the Group, as equipped with self-designed and developed sequence optimization software, can obtain the optimal sequences that affect the stability of key areas and effectively increase antigen expression. The process of CMC (Chemistry, Manufacturing and Controls) is simple, which could shorten product development period and enable rapid industrialization of research achievements. Phase I of the mRNA vaccine production base of the Group has a designed capacity of 100 million doses and is currently in the validation stage.

We cannot guarantee that we will ultimately develop or commercialize Bivalent COVID-19 mRNA Vaccine successfully. Considering several unpredictable factors in the process of clinical trials and the results and timing of clinical trials, evaluations and approvals are subject to uncertainty. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, April 16, 2023

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.